Search results
Showing 3501 to 3550 of 4091 results for patient
indicates active airway inflammation, identifying non-responsiveness in treated patients may help demonstrate good asthma control with...
impact on bed occupancy rates. Current figures suggest that 22% of hospital patients are waiting for a social care assessment so that...
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
knowledge, the committee recommended that biopsies should be considered for patients with a single lung lesion to rule out primary lung...
underlying cause of RCSE, its duration and management. The majority, if not all patients with RCSE are managed in an ICU. There are no...
NICE says paperclip-sized sensor could help thousands monitor heart condition from home
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.
Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)
NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
NICE has developed a medtech innovation briefing (MIB) on fasciotens for abdominal wall closure .
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...
committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier
More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
without N-acetylcysteine.The committee did not consider it necessary for all patients being offered iodine-based contrast media to be...
Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds?
without N-acetylcysteine.The committee did not consider it necessary for all patients being offered iodine-based contrast media to be...
combination treatment with levothyroxine and liothyronine in small subgroups of patients. The committee were aware that some people...
Discontinued Reference number: GID-TA11124
Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]
Discontinued Reference number: GID-TA11175
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Discontinued Reference number: GID-TA10702
Harmful sexual behaviour among children and young people (NG55)
This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.
Online help programme recommended for people with eating disorders
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
What is the clinical and cost effectiveness of preoperative optimisation clinics for older people?
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
evidence was identified comparing LMWH with UFH in this high-risk group of patients. The committee noted that people who take a vitamin...
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
Discontinued Reference number: GID-TAG402
This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.
In development Reference number: GID-MT591 Expected publication date: TBC
Discontinued Reference number: GID-TAG444
Physical activity: encouraging activity in the community (QS183)
This quality standard covers how local strategy, policy and planning and improvements to the built or natural physical environment such as public open spaces, workplaces and schools can encourage and support people of all ages and all abilities to be physically active and move more. It describes high-quality care in priority areas for improvement.
View quality statements for QS183Show all sections
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
Optical Coherence Tomography to guide percutaneous coronary intervention
In development Reference number: GID-IPG10394 Expected publication date: TBC
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]
Discontinued Reference number: GID-TA11256
Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]
Discontinued Reference number: GID-TA11205
In development Reference number: GID-TA11455 Expected publication date: TBC
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued Reference number: GID-TA10970
Discontinued Reference number: GID-TA11119
Discontinued Reference number: GID-TA11120
Masitinib for previously treated moderate Crohn's disease [ID1239]
Discontinued Reference number: GID-TA11188
Discontinued Reference number: GID-TA11206
Discontinued Reference number: GID-TA11207
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210